Trials / Completed
CompletedNCT00000209
Buprenorphine Dosing Interval - 5
Buprenorphine Dosing Interval
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (planned)
- Sponsor
- National Institute on Drug Abuse (NIDA) · NIH
- Sex
- All
- Age
- 21 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore the feasibility of extending the dosing interval of well maintained buprenorphine patients to 48 and 72 hours, leading to eventual 3 times/week dosing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Buprenorphine |
Timeline
- Start date
- 1992-11-01
- First posted
- 1999-09-21
- Last updated
- 2005-08-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00000209. Inclusion in this directory is not an endorsement.